BioAtla, Inc.
BCAB evidence brief
What we can confirm
- BioSniper Score:
- 6.5 / 10
- Market Cap:
- $2.3M
- Lead Asset:
- ba3182 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for BCAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCAB
BioAtla, Inc. (BCAB) is a US-based biotech developing conditionally active biologics (CABs) that exploit tumor microenvironment acidity to target validated antigens, with ongoing Phase 2 trials for mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, and a Phase 1 trial for BA3182.
Key risk: Cash runway risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.3M
Cash Runway
—
Lead Asset
ba3182 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 5 clinical trials for BioAtla, Inc..
BioAtla, Inc. (BCAB) is a US-based biotech developing conditionally active biologics (CABs) that exploit tumor microenvironment acidity to target validated antigens, with ongoing Phase 2 trials for mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, and a Phase 1 trial for BA3182.
- BioAtla's CAB platform targets tumor antigens by exploiting pH differences between acidic tumor microenvironments and healthy tissue [sec_mda · as of 2026-08-13].
- As of 2026-06-30, cash & equivalents were $1.5M, net income was $0.5M, and shareholders' equity was -$36.2M [sec].
- Accumulated deficit was $551.5M as of June 30, 2026, primarily from R&D and G&A costs [sec_mda · as of 2026-08-13].
- Ongoing Phase 2 trials include mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071); Phase 1 trial for BA3182 is also ongoing [sec · filed 2026-06-03].
- In March 2025, BioAtla implemented a 30% workforce reduction and reduced its lease footprint by almost half to lower costs and extend cash runway [sec_mda · as of 2026-05-15].
What works
- Proprietary CAB platform designed to reduce on-target, off-tumor toxicity by selective binding in acidic tumor microenvironments [sec_mda · as of 2026-08-13].
- Multiple ongoing Phase 2 trials across different candidates (mecbotamab vedotin, ozuriftamab vedotin, evalstotug) targeting validated antigens [sec · filed 2026-06-03].
- Fast Track regulatory status for ozuriftamab vedotin (BA3021) in head and neck cancer [pipeline].
What to weigh
- Accumulated deficit of $551.5M as of June 30, 2026, with no expectation of meaningful product revenue in the foreseeable future [sec_mda · as of 2026-08-13].
- Cash & equivalents only $1.5M as of 2026-06-30, indicating very limited financial runway [sec].
- Company has initiated a formal process to explore strategic options including asset sales or partnerships, with no assurance of any agreement [sec_mda · as of 2026-08-13].
- Shareholders' equity is deeply negative at -$36.2M as of 2026-06-30 [sec].
From the filings
Quoted directly from source documents.
CAB platform exploits tumor acidity for selective binding
“Our novel CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy tissue. Unlike healthy tissue, the tumor microenvironment is acidic, and we have designed our antibodies to selectively bind to their targets on tumor cells under acidic pH conditions but not on targets in normal tissues.”
SEC MD&A · August 13, 2026
Accumulated deficit and cash position
“As of June 30, 2026, we had an accumulated deficit of $551.5 million.”
SEC MD&A · August 13, 2026
Ongoing Phase 2 trials
“ongoing Phase 2 clinical trials of mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), evalstotug (BA3071), and the ongoing Phase 1 clinical trial of BA3182”
SEC filings · June 3, 2026
Workforce reduction and cost-cutting
“a restructuring in March 2025 that included a 30% workforce reduction, and a reduction in our lease footprint by almost half in June 2025.”
SEC MD&A · May 15, 2026
Catalyst timeline
- 2018-02-15 · Phase 2 start for mecbotamab vedotin (BA3011) in advanced solid tumors — Ongoing Phase 2 trial; no recent data readout announced.
- 2021-03-17 · Phase 2 start for BA3011 in metastatic NSCLC — Trial in combination with PD-1 inhibitor; results pending.
- 2022-12-13 · Phase 2 start for ozuriftamab vedotin (BA3021) in head and neck cancer — Fast Track status; trial ongoing.
- 2023-07-14 · Phase 1 start for BA3182 (CAB-EpCAM x CAB-CD3) — Bispecific T-cell engager; early-stage trial.
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash & equivalents only $1.5M as of 2026-06-30, insufficient to sustain operations without new funding or partnerships [sec].
- No near-term revenue — Company does not expect meaningful product revenue for the foreseeable future, relying on cost cuts and strategic options [sec_mda · as of 2026-08-13].
- Strategic uncertainty — Formal process to explore sale of assets or partnerships with no assurance of outcome [sec_mda · as of 2026-08-13].
- Negative equity — Shareholders' equity of -$36.2M as of 2026-06-30 indicates accumulated losses exceed assets [sec].
What to watch
- Outcome of the formal strategic options process, including potential asset sales or partnerships [sec_mda · as of 2026-08-13].
- Progress of Phase 2 trials for mecbotamab vedotin, ozuriftamab vedotin, and evalstotug [sec · filed 2026-06-03].
- Cash runway and any new financing or cost-containment measures [sec].
- Regulatory updates, particularly Fast Track status for ozuriftamab vedotin [pipeline].
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run BioAtla, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioAtla, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income $452K
Lead: Phase 2
7 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$2.3M
| Holder | Shares | Value |
|---|---|---|
| acorn capital advisors, llc | 5,406,345 | $865K |
| millennium management llc | 2,756,674 | $444K |
| vanguard capital management llc | 1,649,252 | $266K |
| geode capital management, llc | 689,182 | $111K |
| deutsche bank ag\ | 525,352 | $84K |
| renaissance technologies llc | 510,514 | $82K |
| blackrock, inc. | 480,931 | $77K |
| citadel advisors llc | 435,675 | $70K |
| ubs group ag | 375,569 | $60K |
| marshall wace, llp | 277,630 | $44K |
Showing top 10 of 36 institutional holders of BioAtla, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 8.9%
- Days to cover
- 2.9
- Shares short
- 147,268
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCAB short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioAtla, Inc.?
BioAtla, Inc. (BCAB) is a US-based biotech developing conditionally active biologics (CABs) that exploit tumor microenvironment acidity to target validated antigens, with ongoing Phase 2 trials for mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, and a Phase 1 trial for BA3182.
What is BioAtla, Inc.'s lead drug candidate?
BioAtla, Inc.'s most advanced tracked candidate is ba3182 (Phase 1) for Advanced Adenocarcinoma.
Who is the CEO of BioAtla, Inc.?
Dr. Jay M. Short Ph.D. is the chief executive officer of BioAtla, Inc. (BCAB).
Where is BioAtla, Inc. headquartered?
BioAtla, Inc. (BCAB) is headquartered in San Diego, CA, United States.
What therapeutic areas does BioAtla, Inc. focus on?
BioAtla, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.